tetano
Editor, Senior Moderator
BMC Infect Dis
. 2023 Jun 29;23(1):440.
doi: 10.1186/s12879-023-08424-4. Effect of hydrogen/oxygen therapy for ordinary COVID-19 patients: a propensity-score matched case-control study
Yingying Zeng[SUP] #[/SUP][SUP] 1 2 [/SUP], Weijie Guan[SUP] #[/SUP][SUP] 3 [/SUP], Kai Wang[SUP] #[/SUP][SUP] 1 2 [/SUP], Zhijun Jie[SUP] 1 2 [/SUP], Xu Zou[SUP] 4 [/SUP], Xiaoping Tan[SUP] 5 [/SUP], Xinyu Li[SUP] 6 [/SUP], Xiaohua Chen[SUP] 7 [/SUP], Xiaoting Ren[SUP] 1 2 [/SUP], Junhong Jiang[SUP] 8 [/SUP], Zeguang Zheng[SUP] 3 [/SUP], Jindong Shi[SUP] 9 10 [/SUP], Nanshan Zhong[SUP] 11 [/SUP]
Affiliations
Background: Hydrogen/oxygen therapy contribute to ameliorate dyspnea and disease progression in patients with respiratory diseases. Therefore, we hypothesized that hydrogen/oxygen therapy for ordinary coronavirus disease 2019 (COVID-19) patients might reduce the length of hospitalization and increase hospital discharge rates.
Methods: This retrospective, propensity-score matched (PSM) case-control study included 180 patients hospitalized with COVID-19 from 3 centers. After assigned in 1:2 ratios by PSM, 33 patients received hydrogen/oxygen therapy and 55 patients received oxygen therapy included in this study. Primary endpoint was the length of hospitalization. Secondary endpoints were hospital discharge rates and oxygen saturation (SpO[SUB]2[/SUB]). Vital signs and respiratory symptoms were also observed.
Results: Findings confirmed a significantly lower median length of hospitalization (HR = 1.91; 95% CIs, 1.25-2.92; p < 0.05) in the hydrogen/oxygen group (12 days; 95% CI, 9-15) versus the oxygen group (13 days; 95% CI, 11-20). The higher hospital discharge rates were observed in the hydrogen/oxygen group at 21 days (93.9% vs. 74.5%; p < 0.05) and 28 days (97.0% vs. 85.5%; p < 0.05) compared with the oxygen group, except for 14 days (69.7% vs. 56.4%). After 5-day therapy, patients in hydrogen/oxygen group exhibited a higher level of SpO[SUB]2[/SUB] compared with that in the oxygen group (98.5%±0.56% vs. 97.8%±1.0%; p < 0.001). In subgroup analysis of patients received hydrogen/oxygen, patients aged < 55 years (p = 0.028) and without comorbidities (p = 0.002) exhibited a shorter hospitalization (median 10 days).
Conclusion: This study indicated that hydrogen/oxygen might be a useful therapeutic medical gas to enhance SpO[SUB]2[/SUB] and shorten length of hospitalization in patients with ordinary COVID-19. Younger patients or those without comorbidities are likely to benefit more from hydrogen/oxygen therapy.
Keywords: Hydrogen/oxygen therapy; Length of hospitalization; Ordinary COVID-19 patients; Propensity-score matched.
. 2023 Jun 29;23(1):440.
doi: 10.1186/s12879-023-08424-4. Effect of hydrogen/oxygen therapy for ordinary COVID-19 patients: a propensity-score matched case-control study
Yingying Zeng[SUP] #[/SUP][SUP] 1 2 [/SUP], Weijie Guan[SUP] #[/SUP][SUP] 3 [/SUP], Kai Wang[SUP] #[/SUP][SUP] 1 2 [/SUP], Zhijun Jie[SUP] 1 2 [/SUP], Xu Zou[SUP] 4 [/SUP], Xiaoping Tan[SUP] 5 [/SUP], Xinyu Li[SUP] 6 [/SUP], Xiaohua Chen[SUP] 7 [/SUP], Xiaoting Ren[SUP] 1 2 [/SUP], Junhong Jiang[SUP] 8 [/SUP], Zeguang Zheng[SUP] 3 [/SUP], Jindong Shi[SUP] 9 10 [/SUP], Nanshan Zhong[SUP] 11 [/SUP]
Affiliations
- PMID: 37386364
- DOI: 10.1186/s12879-023-08424-4
Background: Hydrogen/oxygen therapy contribute to ameliorate dyspnea and disease progression in patients with respiratory diseases. Therefore, we hypothesized that hydrogen/oxygen therapy for ordinary coronavirus disease 2019 (COVID-19) patients might reduce the length of hospitalization and increase hospital discharge rates.
Methods: This retrospective, propensity-score matched (PSM) case-control study included 180 patients hospitalized with COVID-19 from 3 centers. After assigned in 1:2 ratios by PSM, 33 patients received hydrogen/oxygen therapy and 55 patients received oxygen therapy included in this study. Primary endpoint was the length of hospitalization. Secondary endpoints were hospital discharge rates and oxygen saturation (SpO[SUB]2[/SUB]). Vital signs and respiratory symptoms were also observed.
Results: Findings confirmed a significantly lower median length of hospitalization (HR = 1.91; 95% CIs, 1.25-2.92; p < 0.05) in the hydrogen/oxygen group (12 days; 95% CI, 9-15) versus the oxygen group (13 days; 95% CI, 11-20). The higher hospital discharge rates were observed in the hydrogen/oxygen group at 21 days (93.9% vs. 74.5%; p < 0.05) and 28 days (97.0% vs. 85.5%; p < 0.05) compared with the oxygen group, except for 14 days (69.7% vs. 56.4%). After 5-day therapy, patients in hydrogen/oxygen group exhibited a higher level of SpO[SUB]2[/SUB] compared with that in the oxygen group (98.5%±0.56% vs. 97.8%±1.0%; p < 0.001). In subgroup analysis of patients received hydrogen/oxygen, patients aged < 55 years (p = 0.028) and without comorbidities (p = 0.002) exhibited a shorter hospitalization (median 10 days).
Conclusion: This study indicated that hydrogen/oxygen might be a useful therapeutic medical gas to enhance SpO[SUB]2[/SUB] and shorten length of hospitalization in patients with ordinary COVID-19. Younger patients or those without comorbidities are likely to benefit more from hydrogen/oxygen therapy.
Keywords: Hydrogen/oxygen therapy; Length of hospitalization; Ordinary COVID-19 patients; Propensity-score matched.